DI NUNNO, VINCENZO
 Distribuzione geografica
Continente #
AS - Asia 2.688
NA - Nord America 2.557
EU - Europa 1.333
AF - Africa 208
SA - Sud America 168
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.960
Nazione #
US - Stati Uniti d'America 2.514
SG - Singapore 807
VN - Vietnam 710
CN - Cina 614
IT - Italia 261
GB - Regno Unito 200
SE - Svezia 178
HK - Hong Kong 177
DE - Germania 146
BR - Brasile 111
FR - Francia 90
NL - Olanda 90
SC - Seychelles 86
RU - Federazione Russa 83
KR - Corea 76
IN - India 74
IE - Irlanda 72
CH - Svizzera 58
JP - Giappone 51
BD - Bangladesh 50
FI - Finlandia 49
CI - Costa d'Avorio 46
ZA - Sudafrica 29
TG - Togo 28
AR - Argentina 25
ID - Indonesia 23
PH - Filippine 21
CA - Canada 18
BG - Bulgaria 17
MX - Messico 16
BE - Belgio 15
TH - Thailandia 15
AT - Austria 13
EE - Estonia 12
JO - Giordania 11
PL - Polonia 11
UA - Ucraina 11
TR - Turchia 9
TW - Taiwan 9
EC - Ecuador 8
PK - Pakistan 8
MY - Malesia 7
UZ - Uzbekistan 7
ES - Italia 6
NG - Nigeria 6
SA - Arabia Saudita 6
VE - Venezuela 6
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
AU - Australia 4
IQ - Iraq 4
LT - Lituania 4
PE - Perù 4
CL - Cile 3
CO - Colombia 3
DZ - Algeria 3
EG - Egitto 3
BB - Barbados 2
BY - Bielorussia 2
KG - Kirghizistan 2
NI - Nicaragua 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
TN - Tunisia 2
UY - Uruguay 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
CD - Congo 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EU - Europa 1
GE - Georgia 1
GN - Guinea 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
NO - Norvegia 1
OM - Oman 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 6.960
Città #
Singapore 581
Ashburn 295
Chandler 239
Santa Clara 179
Hong Kong 162
San Jose 158
Fairfield 150
Hanoi 148
Southend 144
Hefei 143
Ho Chi Minh City 139
Beijing 90
Seattle 80
Dublin 72
Houston 72
Princeton 72
Boardman 69
Woodbridge 67
Dong Ket 65
Seoul 65
Wilmington 60
Bern 55
Cambridge 52
Ann Arbor 49
Council Bluffs 48
Lauterbourg 48
Los Angeles 48
Abidjan 46
Helsinki 45
Bologna 41
Tokyo 33
New York 32
Da Nang 30
Lomé 28
Buffalo 27
Milan 26
Berlin 25
Dallas 23
Haiphong 22
Frankfurt am Main 20
Redondo Beach 20
Sofia 17
London 16
Chicago 15
São Paulo 15
Westminster 15
Jakarta 14
Tianjin 14
Bengaluru 13
Brussels 13
Guangzhou 13
Shanghai 13
Turin 13
Johannesburg 12
Redwood City 12
Amman 11
Des Moines 10
Nanjing 10
Rome 10
Biên Hòa 9
Florence 9
Naples 9
Olalla 9
Redmond 9
Denver 8
Falkenstein 8
Falls Church 8
Hải Dương 8
San Diego 8
Thái Bình 8
Yubileyny 8
Boston 7
Boydton 7
Montreal 7
Orem 7
San Francisco 7
Warsaw 7
Zhengzhou 7
Changsha 6
Glasgow 6
Hangzhou 6
Phoenix 6
Shenyang 6
Shenzhen 6
Thái Nguyên 6
Xi'an 6
Brooklyn 5
Bühl 5
Bắc Ninh 5
Bến Tre 5
Cardiff 5
Forlì 5
Harbin 5
Jinan 5
Kyoto 5
Manila 5
Memphis 5
Montescudo 5
Nha Trang 5
Padua 5
Totale 4.272
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 229
Circulating tumor cells in genitourinary tumors 214
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 207
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 196
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 186
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 168
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. 166
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 165
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 161
Glioblastoma: Emerging treatments and novel trial designs 161
Immune checkpoint inhibitors for metastatic bladder cancer 156
The clinical and prognostic role of ALK in glioblastoma 155
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 152
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 148
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3 147
The human microbiota and prostate cancer: Friend or foe? 146
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? 143
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study 143
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem 137
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 136
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 135
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review 133
Idh1 non-canonical mutations and survival in patients with glioma 128
IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas 126
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study 126
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? 126
Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets 125
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 123
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 121
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 118
Meningioma: Not always a benign tumor. A review of advances in the treatment of meningiomas 118
Machine learning in neuro-oncology: toward novel development fields 114
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 112
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 109
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 108
Rare Primary Central Nervous System Tumors in Adults: An Overview 108
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment 107
Optimizing renal function and outcome of patients with cT2 renal cell carcinoma 105
How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis 104
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 99
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 99
Gender- and Grade-Dependent Activation of Androgen Receptor Signaling in Adult-Type Diffuse Gliomas: Epigenetic Insights from a Retrospective Cohort Study 98
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light 98
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 91
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 88
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 84
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 73
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 73
Targeting Mitochondria in Glioma: New Hopes for a Cure 72
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 70
Cabazitaxel in metastatic prostate cancer 63
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 57
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 52
Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study 51
The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma 49
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 46
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? 38
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 32
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 32
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes 28
N-Myc a key gene promoting a worst prostate cancer progression 27
Future perspectives for personalized immunotherapy in renal cell carcinoma 26
Immunohistochemical Characterization of Tumor Microenvironment Analysis in Glioblastoma IDH-Wildtype 24
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8 23
null 22
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study 21
MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas 18
Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma 18
Totale 7.134
Categoria #
all - tutte 23.407
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.407


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021155 0 0 0 0 0 0 0 0 0 0 0 155
2021/2022609 12 18 15 24 53 22 9 61 56 59 187 93
2022/2023974 90 106 42 100 64 120 28 67 181 37 52 87
2023/2024309 44 62 25 34 19 45 17 26 8 18 2 9
2024/20251.229 65 165 108 86 236 62 64 34 9 115 79 206
2025/20263.130 231 354 266 213 298 151 388 146 571 249 174 89
Totale 7.134